July 22, 2021
The new stimulant ADHD medication AZSTARYS is now available for the treatment of ADHD symptoms in patients aged 6 years and older. A once-daily methylphenidate in capsule form, AZSTARYS comprises 70% extended-release serdexmethylphenidate and dexmethylphenidate with 30% immediate-release dexmethylphenidate.
AZSTARYS was approved by the FDA earlier this year, following a double-blind, randomized, placebo-controlled, phase 3 study of 150 children aged 6 to 12 years who had been diagnosed with ADHD. The study found symptom improvement without serious adverse side effects.
Perry J. Sternberg, President and CEO of Corium, Inc., said that AZSTARYS “provides patients with ADHD, their caregivers, and their clinicians with a first-of-its-kind treatment that offers both rapid and extended ADHD symptom improvement because of the dual action of its formulation using the prodrug SDX with IR MPH.”